Post-traumatic stress disorder, or PTSD, is a common mental illness among veterans. According to the Department of Veteran Affairs, 11% to 30% of veterans who served in foreign wars experience PTSD, far higher than the estimated 6% of the general population. PTSD manifests in many ways, ranging from depression to chronic fatigue. The FDA’s decision to approve Spravato, an esketamine nasal spray, to treat depression and suicidal ideations marked the beginning of a psychedelic revolution in mental healthcare. Researchers believe that ketamine could also play a role in treating other mental health conditions, including PTSD and its many symptoms. Let’s take a look at ketamine’s promise in treating PTSD and how KetamineOne Capital Ltd. (NEO: MEDI) (OTC: KONEF) (FFT: MY0) (“Ketamine One” or the “Company”) aims to bring treatments to veterans and other sufferers of mental health conditions.
Ketamine Shows PromiseKetamine has shown the potential to treat PTSD in several clinical studies. For example, a 2014 study found that intravenous ketamine was associated with significant and rapid reductions in PTSD symptom severity, compared with midazolam, when assessed 24 hours after infusion. In addition, researchers reported that the treatment was generally well-tolerated without persistent dissociative symptoms. More recently, a 2021 study conducted by Mount Sinai researchers found that repeated infusions with ketamine over two weeks significantly reduced symptom severity in many patients while also helping minimize depression symptoms. While improvement occurred after just 24 hours, the benefit was “significantly greater” at two weeks and lasted ~30 days.
Bringing Treatments to VeteransKetamine infusion centers are becoming increasingly common across North America. For example, Ketamine One (NEO: MEDI) (OTC: KONEF) (FFT: MY0) recently signed a non-binding letter of intent with Veteran Services USA to lease 5,000 sq. ft. of space over five years in Blue Island, Illinois, to provide ketamine-assisted therapies. Its goal is to create a first-of-its-kind healing experience for veterans who have PTSD. “We are very proud to be part of an important project such as this with Veteran Services USA, which will allow KetamineOne to showcase its innovative approach to care and treatment by addressing veterans’ unique needs,” said Interim CEO Adam Deffett. “Our company sees an immediate need for its services and has a special opportunity to help.”
Part of a Broader PictureKetamine’s potential is just starting to be realized, and the Company plans to build a leading network of clinics. There are more than 200 active clinical trials involving ketamine in the United States, according to ClinicalTrials.gov. Researchers are evaluating the breakthrough drug to treat conditions like epilepsy, bipolar depression, postpartum depression, perinatal depression, cognitive dysfunction, autism spectrum disorder, and countless other conditions. In the meantime, Ketamine One (NEO: MEDI) (OTC: KONEF) (FFT: MY0) aims to consolidate medical clinics and become a North American leader in mental health treatments. Currently, the Company has 16 clinics across North America and acquired a contract research organization (CRO) to expand into the clinical side of the industry.
Looking AheadKetamine has shown tremendous potential for treating PTSD, but that’s just scratching the surface of what’s possible. Ketamine One’s (NEO: MEDI) (OTC: KONEF) (FFT: MY0) acquisition of KGK Science, a CRO, brings 24 years of experience across pharmaceuticals, cannabis, and emerging psychedelics. In conjunction with its network of clinics, the company is well-positioned to become a leader in conducting cutting-edge clinical research in the space. For more information, visit the Company’s website or download their investor presentation. Click here to receive an investor presentation and corporate updates Disclaimer The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/ The post Ketamine Offers Promise to Veterans with PTSD appeared first on CannabisFN. ketamine psychedelic depression ptsd psychedelics otc fda research
Microdose Announces Wesana Health as Wonderland Platinum Sponsor
Public Companies2 days ago
New study suggests that breastfeeding may help prevent cognitive decline
Law & Regulation2 days ago
Small Pharma On a Role With Price Surge and Major Milestones
Private Companies2 days ago
Small Pharma On a Roll With Price Surge and Major Milestones
Private Companies2 days ago
Microdose Announces Tabula Rasa Ventures as Wonderland Silver Sponsor
Markets & Investing2 days ago
The Tao and the Dharma: A Trip Report of Jon Hopkins’ Music for Psychedelic Therapy
Psilocybin2 days ago
Could Psilocybin Ease the Pain of SUNHA Headaches?
Psilocybin1 day ago